MindImmune Therapeutics is developing a therapeutic antibody that targets the peripheral immune system to mitigate the immune attack on the brain associated with Alzheimer’s disease. This approach aims to address the underlying pathology of Alzheimer’s by preventing neuroinflammation and preserving cognitive function.
Funding
$14.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Alzheimer's disease is characterized by an immune system attack on the brain, leading to neuroinflammation and cognitive decline. Current treatments do not adequately address the underlying immune-related pathology of the disease.
Solution
MindImmune Therapeutics is developing a novel therapeutic antibody that targets the peripheral immune system to mitigate the immune attack on the brain associated with Alzheimer’s disease. By blocking this immune assault, the therapy aims to reduce neuroinflammation and preserve cognitive function. The company's approach is based on the understanding that the nervous and immune systems are integrated, and that targeting the immune system can offer a new avenue for treating brain diseases like Alzheimer's. The antibody is designed to act peripherally, preventing immune cells from infiltrating the brain and causing further damage.
Target Audience
The primary target audience includes individuals at risk of or diagnosed with Alzheimer's disease, as well as their caregivers and healthcare providers.
Features
- Novel therapeutic antibody targeting the peripheral immune system.
- Designed to block the immune attack on the brain in Alzheimer's disease.
- Aims to reduce neuroinflammation.
- Seeks to preserve cognitive function.